📷 ADSTEM Inj. Overview
Our company is currently developing treatments for moderate to severe subacute and chronic atopic dermatitis, with Phase 1 clinical trials underway at Chungnam National University Hospital.
We are continuing research and development to obtain approval for adult stem cell therapy products through Phase 2 and Phase 3 clinical trials.
Our ADSTEM Inj. targets moderate to subacute and chronic atopic dermatitis.
📷 Usage Volume
Low Dose 1.0 x 108 cell / 10 ml / syringe
High Dose 3.0 x 108 cell / 10 ml / 3 syringes
One-time intravenous administration of autologous adipose-derived stem cells
EHL-Keycell is a cell therapy drug that injects minimally manipulated adipocytes derived from autologous adipose tissue into a sterile physiological saline, which has been separated from the patient with minimal manipulation. It is mainly used in plastic surgeries to treat subcutaneous fat deficiency in areas such as the forehead, cheeks and nasolabial fold.
In addition, this process is safer and more effective than conventional medical devices, as the patient’s own adipose tissue is collected, and the cells isolated by simple manipulation before being suspended in a sterile physiological saline solution.
In 2017, EHL-Keycell will apply to the Ministry of Food and Drug Safety for approval as a biological agent.
‘Keycell-IM’ is a cell therapy product filled with activated immune cells collected by drawing blood from a patient and separating the PBMC from the blood. It is under research & development as an anti-cancer cell treatment agent.
We are developing the ‘Keycell-IM’ product with the goal of applying for the clinical trial plan approval from the Korean Ministry of Food and Drug Safety in the second half of 2017.
PBMC (Peripheral Blood Mononuclear Cell) is isolated from the autologous serum and culture for 2 weeks
Under development with the aim of targeting 4 major cancer types
Established the current process and completed a single dose toxicity test
Repeated dose toxicity studies in progress
Lymphocyte marker
NK cells: CD3-CD56+ (CD16+)
NKT cells: CD3+CD56+
T cells: CD3+CD56-CD19-
B cells: CD19+CD56-
NKG2D express in activated NK and T cells (effector cell)
Ex vivo expanded killer cell has high cytotoxicity against cancer
Immune cells isolated from blood and activated
Activated immune cells recognize specific cancer cell antigens and selectively destroys cancer cells without attacking normal cells
Increases the immunity of the body to promote disease defences
The immune cell can be stored
and used at a later date
